Meeting
2024 ASCO Genitourinary Cancers Symposium
Low- and high-volume disease in mHSPC, from CHAARTED to PSMA-PET: An international multicenter retrospective study.
Authors
Lena Unterrainer
Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA
Lena Unterrainer , Thomas A. Hope , Wolfgang P. Fendler , Honest Ndlovu , Francesco Barbato , Mike Sathekge , Ken Herrmann , Johannes Czernin , Jeremie Calais
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Diagnostics and Imaging
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 44)
DOI
10.1200/JCO.2024.42.4_suppl.44
Abstract #
44
Poster Bd #
B1
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Do bone scans over-stage disease compared to PSMA PET? An international multicenter retrospective study with blinded independent readers.
First Author: Wolfgang P. Fendler
Poster
2023 ASCO Annual Meeting
A study of prospective monitoring of patients with recurrent prostate cancer using serial PSMA imaging (18F-DCFPyL).
First Author: Mohammad O. Atiq
Poster
2023 ASCO Genitourinary Cancers Symposium
A retrospective review of the benefits vs. safety implications of prednisolone during docetaxel chemotherapy alongside androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC).
First Author: Molly Jameson
Poster
2016 Genitourinary Cancers Symposium
Predictive value of bone scan index using computer-aided diagnosis system for bone scans in patients receiving first-line hormone therapy for metastatic hormone-sensitive prostate cancer.
First Author: Yasuhide Miyoshi